Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals Q3 2026 Earnings Results & Report

CNS Pharmaceuticals logo
$3.28 +0.39 (+13.49%)
As of 02:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CNS Pharmaceuticals beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.24 versus the -$0.27 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

CNS Pharmaceuticals EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CNS Pharmaceuticals Q3 2026 Earnings FAQ

CNS Pharmaceuticals (NASDAQ:CNSP) reported earnings of -$0.24 per share for Q3 2026, beating the consensus estimate of -$0.27. The report was announced on Monday, November 16, 2026.

CNS Pharmaceuticals Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas.

The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.

The company has also pursued other experimental compounds for brain and central nervous system conditions. Its work has included clinical development and research; it does not market an established portfolio of approved medicines.

View CNS Pharmaceuticals Profile